MicroRNA 6721 (MIR6721)

MicroRNA 6721 (MIR6721) is a small (~20–24 nucleotides) non-coding RNA molecule found in humans, functioning as part of the miRNA regulatory system. Like other microRNAs, it is transcribed from DNA, processed into a mature form by Drosha and Dicer enzymes, and incorporated into the RNA-induced silencing complex (RISC), where it binds target mRNAs to inhibit their translation or degrade them. Recent evidence shows that serum levels of miR-6721-5p, especially when measured alongside miR-362-3p, can reliably distinguish grade 4 glioma from lower-grade gliomas, with high diagnostic sensitivity and specificity. This makes MIR6721 a promising candidate as a non-invasive biomarker in neuro-oncology. However, there is limited evidence supporting its classification as a therapeutic target, and no drugs are known to act directly on MIR6721. Key findings include: - MIR6721 is used as part of a serum miRNA panel for diagnosis and grade classification of glioma. - Associated biological roles stem from general microRNA involvement in key cellular processes and pathways implicated in cancer. - No direct interactions with drugs, nor established therapeutic mechanisms, nor specific safety concerns are documented for MIR6721. If you require information tailored for therapeutic development or compound screening, MIR6721 is best regarded as a diagnostic or prognostic biomarker rather than a classic drug target.

Other names

hsa-mir-6721MIR6721mir-6721microRNA mir-6721